Truist Securities Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $254

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $256 to $254.